Our results revealed that the transgenic expression of wild-type or mutant LRRK2 shares common PD-hallmark pathways corresponding to downregulated dopamine synthesis and elevated energy production, which may imply that LRRK2-targeting therapy may also be useful for patients with wild-type but overexpressed LRRK2. This evidence concerns the gene LRRK2 and Parkinson disease.